ARIAD Presents Long-Term Durability-of-Response Data from Phase 1 Trial of Iclusig

ARIAD Pharmaceuticals, Inc.

today announced long-term durability-of-response data from its Phase 1 trial of Iclusig® (ponatinib) in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study shows that among chronic-phase (CP) patients, the median durations of major and complete cytogenetic responses, along with major molecular response, have yet to be reached. The median follow-up for CP patients still on study is now more than three years (36.5 months). These data are being featured today at 8:00 a.m. CT in a poster presentation at the Annual Meeting of the American Society of Clinical Oncology